CY1118249T1 - Θεραπευτικες ενωσεις και συναφεις μεθοδοι χρησης - Google Patents

Θεραπευτικες ενωσεις και συναφεις μεθοδοι χρησης

Info

Publication number
CY1118249T1
CY1118249T1 CY20161101048T CY161101048T CY1118249T1 CY 1118249 T1 CY1118249 T1 CY 1118249T1 CY 20161101048 T CY20161101048 T CY 20161101048T CY 161101048 T CY161101048 T CY 161101048T CY 1118249 T1 CY1118249 T1 CY 1118249T1
Authority
CY
Cyprus
Prior art keywords
unions
therapeutic
related methods
phosphatase
disorders
Prior art date
Application number
CY20161101048T
Other languages
English (en)
Inventor
Masaki Suzuki
Kazumi Kondo
Muneaki Kurimura
Krishna Reddy Valluru
Akira Takahashi
Takeshi Kuroda
Haruka Takahashi
Tae Fukushima
Shin Miyamura
Indranath Ghosh
Abhishek Dogra
Geraldine Harriman
Amy Elder
Satoshi Shimizu
Kevin J Hodgetts
Original Assignee
Otsuka Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118249(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co., Ltd filed Critical Otsuka Pharmaceutical Co., Ltd
Publication of CY1118249T1 publication Critical patent/CY1118249T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Στο παρόν περιγράφονται μέθοδοι θεραπευτικής αγωγής διαταραχών με τη χρήση ενώσεων οι οποίες ρυθμίζουν την εμπλουτισμένη σε ραβδωτά σώματα φωσφατάση τυροσίνης (STEP). Παραδειγματικές διαταραχές περιλαμβάνουν σχιζοφρένεια και γνωστικό έλλειμμα.
CY20161101048T 2009-12-31 2016-10-19 Θεραπευτικες ενωσεις και συναφεις μεθοδοι χρησης CY1118249T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29155409P 2009-12-31 2009-12-31
US29155009P 2009-12-31 2009-12-31
US29154409P 2009-12-31 2009-12-31
PCT/US2010/062555 WO2011082337A1 (en) 2009-12-31 2010-12-30 Therapeutic compounds and related methods of use

Publications (1)

Publication Number Publication Date
CY1118249T1 true CY1118249T1 (el) 2017-06-28

Family

ID=44226819

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101048T CY1118249T1 (el) 2009-12-31 2016-10-19 Θεραπευτικες ενωσεις και συναφεις μεθοδοι χρησης

Country Status (28)

Country Link
US (3) US9073890B2 (el)
EP (2) EP3056207B1 (el)
JP (3) JP5753194B2 (el)
KR (1) KR20120115350A (el)
CN (2) CN102883723B (el)
AR (1) AR079814A1 (el)
AU (2) AU2010339423C1 (el)
BR (1) BR112012016392A2 (el)
CA (1) CA2785923C (el)
CO (1) CO6571895A2 (el)
CY (1) CY1118249T1 (el)
DK (1) DK2521549T3 (el)
EA (2) EA028066B1 (el)
ES (1) ES2598577T3 (el)
HK (1) HK1173654A1 (el)
HR (1) HRP20161330T1 (el)
HU (1) HUE030752T2 (el)
IL (1) IL219974A0 (el)
LT (1) LT2521549T (el)
MX (2) MX349476B (el)
MY (1) MY161082A (el)
PH (1) PH12015502823A1 (el)
PL (1) PL2521549T3 (el)
PT (1) PT2521549T (el)
SG (2) SG181523A1 (el)
SI (1) SI2521549T1 (el)
TW (2) TWI591063B (el)
WO (1) WO2011082337A1 (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178592A1 (en) 2009-09-03 2012-04-27 Bristol Myers Squibb Co Quinazolines as potassium ion channel inhibitors
GB2497476B (en) * 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
KR20140048216A (ko) * 2011-06-29 2014-04-23 오츠카 세이야쿠 가부시키가이샤 치료 화합물로서의 퀴나졸린 및 관련된 사용 방법
BR112014000267A2 (pt) * 2011-07-04 2016-09-20 Bayer Ip Gmbh utilização de isoquinolinonas, isoquinolinedionas, isoquinolinetrionas e dihidroisoquinolinonas substituídas ou, em cada caso, sais das mesmas como agentes ativos contra o stress abiótico em plantas
WO2013013614A1 (zh) * 2011-07-28 2013-01-31 南京英派药业有限公司 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
EP2858995A1 (en) * 2012-06-07 2015-04-15 F. Hoffmann-La Roche AG Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
MX356699B (es) 2012-06-11 2018-06-11 Bristol Myers Squibb Co Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilme tilamino) quinazolin-2-il]piridin-3-sulfonamida.
CN102702116B (zh) * 2012-06-13 2014-12-31 华南理工大学 4-(3-氯-4-甲氧基苯胺基)-6-(3-胺基苯基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用
WO2014143609A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
KR20150135359A (ko) 2013-03-14 2015-12-02 컨버진 엘엘씨 브로모도메인-함유 단백질의 억제를 위한 방법 및 조성물
MX2016004964A (es) * 2013-10-16 2016-07-11 Shanghai Yingli Pharm Co Ltd Compuesto heterociclico fusionado, metodo de preparacion del mismo, composicion farmaceutica, y usos del mismo.
SI3089971T1 (sl) 2014-01-01 2020-11-30 Medivation Technologies Llc Spojine in postopki za uporabo
WO2016090296A1 (en) * 2014-12-05 2016-06-09 Subramaniam Ananthan Heterocyclic compounds as biogenic amine transport modulators
KR102139496B1 (ko) 2014-12-15 2020-07-30 더 리젠츠 오브 더 유니버시티 오브 미시간 Egfr 및 pi3k의 소분자 억제제
AU2016361441B2 (en) 2015-11-25 2021-08-12 Convergene Llc Bicyclic BET bromodomain inhibitors and uses thereof
CN109476641B (zh) * 2016-05-24 2022-07-05 基因泰克公司 Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
CN107722012B (zh) * 2016-08-11 2020-05-29 斯福瑞(南通)制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
KR20190093214A (ko) 2016-12-13 2019-08-08 베타 테라퓨틱스 피티와이 리미티드 헤파라나제 억제제 및 그의 용도
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
CN110177791B (zh) 2016-12-20 2022-07-12 阿斯利康(瑞典)有限公司 氨基-三唑并吡啶化合物及其在治疗癌症中的用途
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CA3071534A1 (en) * 2017-08-02 2019-02-07 Northwestern University Substituted fused pyrimidine compounds and uses thereof
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
KR20200110648A (ko) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 비라세믹 혼합물 및 이의 용도
KR20210022656A (ko) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템
CN112566906A (zh) 2018-07-26 2021-03-26 多曼治疗学公司 取代的喹唑啉酮衍生物和它们作为mglur4的正变构调节剂的用途
US11542240B2 (en) 2018-12-20 2023-01-03 Trustees Of Boston University STK19 inhibitors for treatment of cancer
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
KR20230038457A (ko) 2020-06-10 2023-03-20 알리고스 테라퓨틱스 인코포레이티드 코로나바이러스, 피코르나바이러스 및 노로바이러스 감염을 치료하기 위한 항바이러스 화합물
EP4267554A1 (en) 2020-12-22 2023-11-01 Mekanistic Therapeutics LLC Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 4−アミノキナゾリン誘導体およびそれを含有する医薬品
US20020025968A1 (en) * 1998-04-15 2002-02-28 Rifat Pamukcu Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives
ES2360933T3 (es) * 2000-04-27 2011-06-10 Astellas Pharma Inc. Derivados de heteroarilo condensados.
WO2002062767A1 (fr) 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de quinazoline
US20030125344A1 (en) 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
AU2003202263A1 (en) 2002-01-10 2003-07-30 Bayer Healthcare Ag Roh-kinase inhibitors
MXPA04006882A (es) * 2002-01-17 2004-12-06 Neurogen Corp Analogos substituidos de quinazolin-4-ilamina como moduladores de receptores de capsaicina.
EP1581225A1 (en) * 2002-12-13 2005-10-05 Neurogen Corporation Combination therapy for the treatment of pain
JP2006515847A (ja) 2002-12-13 2006-06-08 ニューロジェン・コーポレーション カプサイシン受容体調節剤としてのカルボン酸、ホスフェート又はホスホネート置換キナゾリン−4−イルアミン類縁体
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
CL2004000409A1 (es) 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
CA2520323C (en) * 2003-04-09 2013-07-09 Exelixis, Inc. Tie-2 modulators and methods of use
US20090143399A1 (en) 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2005042501A1 (en) 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
WO2005055813A2 (en) * 2003-12-08 2005-06-23 Agy Therapeutics, Inc. Interaction of nmda receptor with the protein tyrosine phosphatase step in psychotic disorders
DE602005024382D1 (de) * 2004-04-13 2010-12-09 Astellas Pharma Inc Polycyclische pyrimidine als kaliumionenkanal-modulatoren
WO2006058201A2 (en) 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
JP2007084494A (ja) 2005-09-22 2007-04-05 Oncorex Inc Pim−1活性阻害剤
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
US20090306102A1 (en) 2005-12-20 2009-12-10 Eriksen Birgitte L 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
RU2457854C2 (ru) 2005-12-30 2012-08-10 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед Длительное высвобождение нейрегулина для улучшения сердечной функции
DE102006012251A1 (de) 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
CA2652341A1 (en) 2006-05-15 2007-11-22 Senex Biotechnology, Inc. Identification of cdki pathway inhibitors
GB0724349D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008092862A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
EP2402341B1 (en) 2007-03-28 2017-10-25 Saniona A/S Purinyl derivatives and their use as potassium channel modulators
WO2008116909A1 (en) * 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
WO2009000085A1 (en) 2007-06-27 2008-12-31 Painceptor Pharma Corporation Quinoline and quinazoline derivatives useful as modulators of gated ion channels
EP2207781B1 (en) 2007-09-24 2012-11-28 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
US20090192176A1 (en) 2008-01-30 2009-07-30 Wyeth 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
JP5608099B2 (ja) * 2008-01-30 2014-10-15 ジェネンテック, インコーポレイテッド ピラゾロピリミジンpi3k阻害剤化合物および使用方法
EP2445346A4 (en) 2009-06-24 2012-12-05 Genentech Inc OXOHETEROCYCLIC FUSIONED PYRIMIDINE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
US20110077250A1 (en) 2009-06-26 2011-03-31 Ryder Sean Compounds for modulating rna binding proteins and uses therefor
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
SG178592A1 (en) * 2009-09-03 2012-04-27 Bristol Myers Squibb Co Quinazolines as potassium ion channel inhibitors
EP2496081B1 (en) 2009-11-02 2020-03-25 Ariagen, Inc. Ite for cancer intervention and eradication

Also Published As

Publication number Publication date
AU2010339423B9 (en) 2016-12-22
JP2015178517A (ja) 2015-10-08
MX2012007727A (es) 2012-11-22
SI2521549T1 (sl) 2017-01-31
CN102883723A (zh) 2013-01-16
LT2521549T (lt) 2016-11-10
EP2521549A4 (en) 2013-06-05
WO2011082337A1 (en) 2011-07-07
US9630947B2 (en) 2017-04-25
CO6571895A2 (es) 2012-11-30
EP3056207B1 (en) 2018-06-20
TW201630898A (zh) 2016-09-01
SG181523A1 (en) 2012-07-30
TWI601723B (zh) 2017-10-11
HUE030752T2 (en) 2017-05-29
AU2017201175A1 (en) 2017-03-16
EA028066B1 (ru) 2017-10-31
PL2521549T3 (pl) 2017-01-31
JP2013516428A (ja) 2013-05-13
CA2785923A1 (en) 2011-07-07
EP3056207A1 (en) 2016-08-17
EP2521549B1 (en) 2016-08-17
HRP20161330T1 (hr) 2016-12-30
HK1173654A1 (zh) 2013-05-24
MX349476B (es) 2017-07-31
PT2521549T (pt) 2016-10-14
AU2010339423B2 (en) 2016-12-01
JP2017071639A (ja) 2017-04-13
EP2521549A1 (en) 2012-11-14
WO2011082337A8 (en) 2012-07-05
US20170217923A1 (en) 2017-08-03
JP6062999B2 (ja) 2017-01-18
ES2598577T3 (es) 2017-01-27
CN105218516A (zh) 2016-01-06
AU2010339423C1 (en) 2017-03-09
BR112012016392A2 (pt) 2017-10-03
CN102883723B (zh) 2015-09-16
TW201124395A (en) 2011-07-16
AU2010339423A1 (en) 2012-06-14
MY161082A (en) 2017-04-14
CA2785923C (en) 2017-06-06
US20130053341A1 (en) 2013-02-28
IL219974A0 (en) 2012-07-31
DK2521549T3 (en) 2016-11-14
US9073890B2 (en) 2015-07-07
PH12015502823A1 (en) 2018-01-22
EA201790962A1 (ru) 2018-04-30
KR20120115350A (ko) 2012-10-17
TWI591063B (zh) 2017-07-11
US20150307477A1 (en) 2015-10-29
SG10201408789WA (en) 2015-02-27
JP5753194B2 (ja) 2015-07-22
AR079814A1 (es) 2012-02-22
EA201290593A1 (ru) 2013-12-30

Similar Documents

Publication Publication Date Title
CY1118249T1 (el) Θεραπευτικες ενωσεις και συναφεις μεθοδοι χρησης
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
CY1118187T1 (el) Χημικες ενωσεις
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
CY1121182T1 (el) Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1121460T1 (el) Διαμορφωση του μεταγωγεα σηματος και του ενεργοποιητη εκφρασης της μεταγραφης 3 (stat3)
CY1123746T1 (el) Ανθρωποποιημενα tau αντισωματα σε νοσο του alzheimer
CY1123633T1 (el) Ετεροκυκλικες ενωσεις και οι χρησεις αυτων
CY1121653T1 (el) C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EA201490177A1 (ru) Хиназолины как терапевтические соединения и связанные с ними способы их применения
EA201591509A1 (ru) Ингибиторы cdc7
DK3740504T5 (da) CD70 kombinationsterapi
GT201300164A (es) Derivados de biciclo (3.2.1.) octilamida y sus usos
SG10201804385YA (en) Stimulus responsive polymers for the purification of biomolecules
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
AU2018348359A8 (en) Extended release pharmaceutical formulation and methods of treatment